Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Other Non Operating Income: 2021-2024

Historic Other Non Operating Income for Tarsus Pharmaceuticals (TARS) over the last 4 years, with Dec 2024 value amounting to -$1.9 million.

  • Tarsus Pharmaceuticals' Other Non Operating Income rose 46.27% to $98,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$61,000, marking a year-over-year increase of 96.71%. This contributed to the annual value of -$1.9 million for FY2024, which is 1761.54% down from last year.
  • According to the latest figures from FY2024, Tarsus Pharmaceuticals' Other Non Operating Income is -$1.9 million, which was down 1,761.54% from $117,000 recorded in FY2023.
  • Over the past 5 years, Tarsus Pharmaceuticals' Other Non Operating Income peaked at $117,000 during FY2023, and registered a low of -$1.9 million during FY2024.
  • For the 3-year period, Tarsus Pharmaceuticals' Other Non Operating Income averaged around -$776,000, with its median value being -$501,000 (2022).
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Other Non Operating Income skyrocketed by 123.35% in 2023, and later slumped by 1,761.54% in 2024.
  • Yearly analysis of 4 years shows Tarsus Pharmaceuticals' Other Non Operating Income stood at -$987,000 in 2021, then soared by 49.24% to -$501,000 in 2022, then surged by 123.35% to $117,000 in 2023, then tumbled by 1,761.54% to -$1.9 million in 2024.